Crossmark

A Phase 4, Open-Label, Non-Randomized, Multicenter Study to Evaluate Efficacy (and Safety) of Intravenous Administration of Optison for Contrast-Enhanced Echocardiography in Pediatric Patients

Crossref DOI link: https://doi.org/10.1007/s00246-025-03993-4

Published Online: 2025-08-27

Published Print: 2026-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Sabati, Arash

Wang, Shuo

Shivaram, Pushpa

Hawley, Joshua

Thompson, David

Erenberg, Francine

Kutty, Shelby

Kulkarni, Aparna

Doan, Tam T.

Robinson, Joshua D.
Funding

Funding for this research was provided by:

GE Healthcare
License Information

Text and Data Mining valid from 2025-08-27

Version of Record valid from 2025-08-27
More Information

Article History

Received: 20 May 2025

Accepted: 2 August 2025

First Online: 27 August 2025

Declarations

:

: Authors JH and DT are employed by GE Healthcare who provided funding for the study.

: This study was approved and monitored by local internal review boards. Informed consent was obtained from all patients for study participation.

Document is current

Any future updates will be listed below